Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-Infected Subjects ACTG 5200
Michael F. Para(The Ohio State University), Barbara Brizz(Social and Scientific Systems (United States)), Winston Cavert(University of Minnesota Medical Center), Jeff Schouten(The Lundquist Institute), Pablo Tebas(University of Pennsylvania), Eric S. Daar(UCLA Medical Center), Dominic N. Reeds(Washington University in St. Louis), Juan J.L. Lertora(National Institutes of Health Clinical Center), C. J. White(Eloxx Pharmaceuticals (United States)), Kristine B. Patterson(University of North Carolina at Chapel Hill), David B. Weiner(The Wistar Institute), Susan L. Rosenkranz(Harvard University), Yu Song(Institute of Oceanology)
Cited by 11
Related Papers
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
|New England Journal of Medicine|2002|1.1k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891
Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4 <sup>+</sup> T Cells
|Science|1999|872
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352